星空游戏网站免费进入|星空彩票电脑版

摘要/Abstract

摘要：阿尔茨海默病（Alzheimer's disease，AD）是全球共同关注的重大公共卫生课题和日益严重的社会问题，发掘防治AD的新靶标和新药物是当今医药领域亟待破解的难题。越来越多的研究显示，中枢肾素-血管紧张素系统（central rennin-angiotensin system，CRAS）与AD密切相关。本文根据相关文献报道，综述CRAS中血管紧张素II（angiotensin II，Ang II）及其受体（angiotensin II type 1 receptor，AT₁R；angiotensin II type 2 receptor，AT₂R），血管紧张素IV（angiotensin IV，Ang IV）及其受体（angiotensin II type 4 receptor，AT₄R）以及血管紧张素转化酶（angiotensin converting enzyme，ACE）在AD发生发展中的作用，揭示可能成为防治AD的新靶标，提出开发新型抗AD药物的新思路。

关键词:阿尔茨海默病,血管紧张素1型受体,血管紧张素2型受体,血管紧张素4型受体,血管紧张素转化酶

Abstract:Alzheimer's disease (AD) is not only a global major public health issue of common concern, but also an increasingly serious social problem. Developing novel prevention or treatment targets and drugs of AD is an arduous task that remains to be overcome. More and more studies show that central rennin-angiotensin system (CRAS) is closely associated with AD. Based on related literatures, we reviewed the roles of Ang II and its receptors (AT₁R and AT₂R), Ang Ⅳ and its receptor (AT₄R) as well as ACE in AD, and revealed potential targets, and indicated new directions to developing drugs for AD.

Key words:Alzheimer's disease (AD),angiotensin II type 1 receptor (AT₁R),angiotensin II type 2 receptor (AT₂R),angiotensin II type 4 receptor (AT₄R),angiotensin converting enzyme (ACE)

中图分类号:

R964

王超，项国卿，洪浩.中枢肾素-血管紧张素系统与阿尔茨海默病[J]. 神经药理学报, 2012, 2(2): 37-41.

WANG Chao，XIANG Guo-qing，HONG Hao.Central Rennin-angiotensin System and Alzheimer's Disease[J]. Acta Neuropharmacologica, 2012, 2(2): 37-41.

参考文献

[1] Henry W Querfurth, Frank M LaFerla. Alzheimer's disease [J]. N Engl J Med, 2010, 362(4): 329-344.

[2] Nathan Herrmann, Sarah A Chau, Ida Kircanski, et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review [J]. Drugs, 2011, 71(15): 2031-2065.

[3] Martin Paul, Ali Poyan Mehr, Reinhold Kreutz. Physiology of local Renin-Angiotensin Systems [J]. Physiol Rev, 2006, 86(3): 747-803.

[4] John W Wright, Joseph W Harding. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory [J]. Prog Neurobiol, 2004, 72(4): 263-293.

[5] Unger T, Badoer E, Ganten D, et al. Brain angiotensin: Pathway and pharmacology [J]. Circulation, 1988, 77(6 Pt 2): 140-154.

[6] Paul M, Printz M, Harns E. Loculation of renin and converting enzyme in nerve endings of rat [J]. Brain Res, 1985, 334(2): 315-322.

[7] Victor J Dzau, Burt D W, Richard E Pratt. Molecular biology of the rennin angiotensin system [J]. Am J Physiol, 1988, 255(4): F563-573.

[8] Victor J Dzau, Julie Ingelfinger, Richard E Pratt, et al. Identification of rennin and angiotensinogen messenger RNA sequences in mouse and rat brains [J]. Hypertension, 2009, 78(6):544-551.

[9] Manwen Jim, Markus J Wilhelm, Rudolf E Lang. Endogenous tissure rennin-angiotensin systems From molecular biology to therapy [J]. Am J Med, 1988, 84(3A): 28-36.

[10] Michael B Gutman, Douglas L Jones, John Ciriello. Effect of paraventricular nucleus lesions of drinking and pressor responses to ANG II [J]. Am J Physiol (Regul Intergr Conp Physiol), 1988, 255(6 Pt 2): 145-163.

[11] Egemen Savaskan, Christoph Hock, Gianfranco Olivieri, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia [J]. Neurobiol Aging, 2011, 22(4): 541–546.

[12] Savaskan E, Hochli M, Ganten D, et al. Angiotensin II immunoreactivity in the human striatum and hippocampus of elderly controls and patients with senile dementia of the Alzheimer type and multi-infarct dementia [J]. Dement Geriatr Cogn Disord, 1991, 2: 314–323.

[13] Dimitri De Bundel, IIse Smolders, Patrick Vanderheyden, et al. Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy [J].CNS Neurosci Ther, 2009, 15(2): 315-339.

[14] Zhu Dong-lin, Shi Jing-ping, Zhang Ying-dong, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats [J]. PLoS One, 2011, 6(1): e16037.

[15] Li Nien-chen, Lee Austin, Whitmer Rachel, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis [J]. BMJ, 2010, 8(340): b5465.

[16] Tobias V Lanz, Ding Zhao-qing, Peggy P Ho, et al. Angiotensin II sustains brain inflammation in mice via TGF- β [J]. J Clin Invest, 2010, 120(8): 2782–2794.

[17] H Michael Tucker, Muthoni Kihiko-Ehmann, Sarah Wright, et al. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition [J]. J Neurochem, 2010, 75(5): 2172–2177.

[18] John W Wright, Jospeh W Harding. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions [J]. Regul Pept, 1995, 59(3): 269-295.

[19] Zhu Y Z, Chimon G N, Zhu Y C, et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats [J]. Neuroreport, 2000, 11(6): 1191-1194.

[20] Li Jun, Juraj Culman, Heide Hortnagl, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury [J]. FASEB J, 2005, 19(6): 617-619.

[21] Lutz Hein, Gregory S Barsh, Richard E Pratt, et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice [J]. Nature, 1995, 377(6551): 744-747.

[22] Toshihiro Ichiki, Patricia A Labosky, Chiyo Shiota, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor [J]. Nature, 1995, 377(6551): 748-750.

[23] Wang Jun, Lap Ho, Chen Ling-hong, et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease [J]. J Clin Invest, 2007, 117(11): 3393–3402.

[24] Hajjar Ihab, Meaghan Hart, Chen Yu-ling, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial [J]. Arch Intern Med, 2012, 172(5): 442-448.

[25] Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydroclorothiazide on cognitive function and quality of life in hypertensive patients [J]. Am J Hypertens, 1999, 12(11 Pt 1): 1130-1134.

[26] Robert Fogari, Paola Preti, Amedeo Mugellini, et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients [J]. Am J Hypertens, 2002, 15(4): 36A.

[27] Lusine Danielyan, Roman Klein, Leah R Hanson, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease [J]. Rejuvenation Res, 2010, 13(2-3): 195–201.

[28] Emmanuelle Duron, Olivier Hanon. Antihypertensive treatments, cognitive decline, and dementia [J]. J Alzheimers Dis, 2010, 20(3): 903-914.

[29] Jan Jozef Braszko, Anna Walesiuk, Przemyslaw Wielgat. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV [J]. J Renin Angiotensin Aldosterone Syst, 2006, 7(3): 168–174.

[30] Davis CJ, Kramar EA, De A, et al. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation [J]. Neuroscience, 2006, 137(4): 1369–1379.

[31] John W Wright, Eniko A Kramar, Elizabeth D Myers, et al. Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog [J]. Regul Pept, 2003, 113(1-3): 49–56.

[32] Matthew L Hemming, Dannis J Selkoe. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor [J]. J Biol Chem, 2005, 280(450): 37644-37650.

[33] John W Wright, Joseph W Harding. The brain angiotensin IV/AT4 receptor system as a new target for the treatment of Alzheimer's disease [J]. Drug Dev Res, 2010, 70(7): 472–480.

[34] Alberto Arregui, Elaine K Perry, Martin Rossor, et al. Angiotensin converting enzyme in Alzheimer’s disease increased activity in caudate nucleus and cortical areas [J]. J Neurochem, 1982, 38(5): 1490–1492.

[35] Dong Yi-Fei, Keiichiro Kataoka, Yoshiko Tokutomi, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease [J]. FASEB J, 2011, 25(9): 2911-2920.

[36] Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels [J]. J Clin Invest, 1990, 86(4): 1343–1346.

[37] Sergei Danilov, Francoise Savoie, Bertrand Lenoir, et al. Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large scale studies [J]. J Hypertens, 1996, 14(6): 719–727.

[38] Roger Cox, Nourdine Bouzekri, Sabrina Martin, et al. Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides [J]. Hum Mol Genet, 2002, 11(23): 2969–2977.

[39] Skidgel R A, Erdös E G. The broad substrate specificity of human angiotensin I converting enzyme [J]. Clin Exp Hypertens A, 1987, 9(2-3): 243-259.

[40] Hu Jian-guo, Akira Igarashi, Makiko Kamata, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide(Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity [J]. J Biol Chem, 2007, 276(51): 47863-47868.

[41] J Scott Miners, Zoe Van Helmond, Patrick G Kehoe, et al. Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme [J]. Brain Pathol, 2010, 20(4): 794–802.

[42] Zou K, Yamaguchi H, Akaatsu H, et al. Angiotensin- enzyme converts amyloid-protein 1–42(Aβ1–42) to Aβ1–40, and its inhibition enhances brain Aβ deposition [J]. J Neurosci, 2007, 27(32): 8628–8635.

[43] Elizabeth A Eckman, Stephanie K Adams, Frederick J Troendle, et al. Regulation of steady-state β -amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme [J]. J Biol Chem, 2006, 281(41): 30471-30478.

[44] Hemming Matthew L, Selkoe Dennis J, Farris Wesley. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease [J]. Neurobiol Dis, 2007, 26(1): 273-281.

[45] John W Wright, Joseph W Harding. The brain RAS and Alzheimer’s disease [J]. Exp Neurol, 2010, 223(2): 326–333.

中枢肾素-血管紧张素系统与阿尔茨海默病

Central Rennin-angiotensin System and Alzheimer's Disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

[1]	张园青, 林珏, 黄莉.维生素D 对阿尔茨海默病细胞模型中 DNA 甲基化作用研究[J]. 神经药理学报, 2024, 14(6): 39-.
[2]	姚思凡, 张鑫, 沈丽霞.Tau 蛋白在阿尔茨海默病中对线粒体的影响[J]. 神经药理学报, 2024, 14(4): 54-.
[3]	王天旭, 刘慈, 崔永元, 张鑫, 吴苗苗, 沈丽霞.基于网络药理学和分子对接探究槲皮素治疗阿尔茨海默病的作用机制[J]. 神经药理学报, 2024, 14(2): 31-.
[4]	朱静怡, 樊建春, 禹爱梅.普罗布考在保护神经系统中的研究现状[J]. 神经药理学报, 2023, 13(6): 50-.
[5]	张晓然, 刘思远, 杨浩然, 郭轩桐, 范乐豪, 李金达, 金戈, 卢方晋, 朱琳.基于网络药理学探究紫檀芪对阿尔茨海默病的作用及分子机制[J]. 神经药理学报, 2023, 13(5): 1-.
[6]	郭宝, 刘子铭, 景永帅, 张丹参.Wnt信号通路与阿尔茨海默病的相关性及靶点研究[J]. 神经药理学报, 2023, 13(1): 56-.
[7]	司文英, 侯宇清, 孙晓静, 孟宪勇, 董晓华.基因治疗阿尔茨海默病[J]. 神经药理学报, 2022, 12(6): 51-56.
[8]	张志清, 张永财, 刘林轩, 李壬清, 刘济嘉, 杜景考, 姜北, 魏会平, 苏立宁.外泌体ceRNA调控网络与阿尔茨海默病相关性的生物信息学分析[J]. 神经药理学报, 2022, 12(4): 23-40.
[9]	蔡雨珊, 赵帅.PPARβ/δ在神经退行性疾病中的研究进展[J]. 神经药理学报, 2022, 12(4): 41-48.
[10]	吕雪盈, 章正, 罗焕敏.血脑屏障与阿尔茨海默病[J]. 神经药理学报, 2022, 12(4): 58-64.
[11]	戴月英, 赵雨薇, 姚思凡, 等.雌激素介导线粒体途径的神经保护作用研究[J]. 神经药理学报, 2021, 11(3): 33-42.
[12]	丁圣恺, 刘倩倩, 刘新杨, 商亚珍.成年海马神经发生与阿尔茨海默病的关系[J]. 神经药理学报, 2020, 10(6): 48-53.
[13]	黄颖, 霍艳丽, 明越, 郝军荣.高脂饮食与阿尔茨海默病的研究进展[J]. 神经药理学报, 2020, 10(6): 54-59.
[14]	谢彬, 黄志源, 林多朵, 杨福龙, 谢奕彬.针药结合干预阿尔茨海默病抑郁症状效果分析[J]. 神经药理学报, 2020, 10(5): 5-8.
[15]	赵雨薇, 甄艳杰, 戴月英, 沈丽霞.槲皮素对阿尔茨海默症神经保护作用研究[J]. 神经药理学报, 2020, 10(5): 55-64.